Is Mounjaro on LillyDirect? Cash-Pay Vial Status for 2026

Mounjaro now appears on LillyDirect, Eli Lilly’s direct-to-patient pharmacy, and Lilly has signaled a self-pay pathway for it following a November 2025 federal pricing agreement that called for adding Mounjaro at roughly 50% to 60% off list. But as of mid-2026, the well-known discounted vial prices you’ve probably seen, $299, $399, and $449 a month, belong to Zepbound, not Mounjaro, and a firm, consistently published Mounjaro self-pay figure hasn’t fully settled. The short version: if your goal is weight loss and you’re paying cash, Zepbound through LillyDirect remains the confirmed cheaper tirzepatide route, since it’s the same active ingredient at the same doses from the same maker.

Here’s where things actually stand, and why the Mounjaro-versus-Zepbound distinction trips people up.

What’s confirmed right now

Mounjaro is listed on the LillyDirect medicines page, and Lilly’s pricing materials point cash-pay and uninsured patients toward a LillyDirect self-pay option for it. That’s a change from most of 2025, when LillyDirect’s discounted direct-pay program ran for Zepbound only and there was no equivalent for Mounjaro at all.

What hasn’t fully landed is a clear, stable price tag. The November 2025 agreement committed Lilly to offering Mounjaro through LillyDirect at about 50% to 60% below list, but as of this writing the exact self-pay dollar figures aren’t quoted consistently across Lilly’s own channels the way Zepbound’s are. A 50% to 60% cut off Mounjaro’s list price would put it somewhere in the mid-hundreds per month, but until Lilly posts firm numbers, treat any precise figure you see with caution and check LillyDirect directly for current pricing.

Why Mounjaro and Zepbound get confused

Mounjaro and Zepbound are the same molecule, tirzepatide, from the same manufacturer. The difference is the label. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. That single distinction drives nearly everything about cost and access.

The discounted self-pay vial program was built for the weight-loss product. So the $299, $399, and $449 prices that circulate online are Zepbound’s, and applying them to Mounjaro is the most common mistake in cash-pay GLP-1 shopping. Here’s the current landscape.

Mounjaro’s list price is $1,112.16 for a 28-day supply, and Lilly charges the same regardless of which dose you’re on, so a patient starting at 2.5 mg pays the same sticker as someone at 15 mg. The savings card can bring eligible commercial patients to about $25 a month, but it requires a type 2 diabetes diagnosis and excludes anyone on Medicare, Medicaid, or other government coverage.

Why Zepbound is the cash-pay tirzepatide most people use

Consider a scenario where someone wants tirzepatide for weight loss, has no insurance coverage for it, and is comparing routes. Paying retail for Mounjaro pens means roughly $1,000 or more a month. The Mounjaro savings card won’t help, because it’s built around a diabetes prescription. Zepbound vials through LillyDirect, at $299 to $449 depending on dose, deliver the identical active ingredient for a fraction of the retail pen price. For most cash-paying weight-loss patients, that’s the obvious move, and our guide on how to get Zepbound online walks through the steps.

Lilly has also been reshaping the format. A reusable Zepbound multidose pen launched in early 2026, and the self-pay vial prices were trimmed by about $50 across tiers as part of the same federal agreement that’s pulling Mounjaro into the direct-pay world. The best self-pay pricing generally depends on refilling on schedule, so it’s worth confirming the refill terms before you commit.

The clinical case for tirzepatide is strong on the diabetes side too. In the SURPASS-4 trial (Del Prato et al., Lancet 2021), tirzepatide outperformed insulin glargine on blood-sugar control in adults with type 2 diabetes and high cardiovascular risk, which is part of why Mounjaro is so widely prescribed for diabetes in the first place.

If you specifically need Mounjaro

Sometimes the diabetes label is the point. If you have type 2 diabetes and need Mounjaro’s FDA-approved indication for clinical or insurance reasons, your cheapest path is usually insurance plus the savings card if you qualify, and you’ll want to keep an eye on LillyDirect as its Mounjaro self-pay pricing firms up. For more on the retail and discount picture, Mounjaro cash price options breaks it down, and the cost of tirzepatide per month covers the broader pricing math.

If you’re paying cash and open to the compounded route, TrimRx is a cash-pay telehealth program that connects you with licensed providers for physician-prescribed tirzepatide and semaglutide, with monthly pricing across the program’s medications running from $179 to $1,579 depending on the medication and plan. To see what fits, the free assessment quiz takes a few minutes and routes your information to a licensed provider for review.

This article is for general educational purposes and isn’t medical advice. Direct-pay pricing and manufacturer programs change frequently, so verify current Mounjaro and Zepbound pricing with LillyDirect and your prescriber before making decisions.